您好，欢迎来到仪器设备网！ [登录] [免费注册]
仪器设备网
发布求购
位置：首页 > 产品库 > NX-13
立即咨询
咨询类型：
     
*姓名：
*电话：
*单位：
Email：
*留言内容：
请详细说明您的需求。
*验证码：
 
NX-13
本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。
NX-13图片
CAS NO:2389235-01-0
包装与价格：
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议
100mg电议

产品介绍

NX-13是一种一流的，具有口服活性的肠道限制剂，选择性靶向并激活 NLRX1 通路，诱导免疫代谢改变。NX-13 可降低炎症性肠病的炎症反应。NX-13 可用于克罗恩病和溃疡性结肠炎的研究。

Cas No.2389235-01-0
分子式C24H21N3O3
分子量399.44
溶解度DMSO : 135 mg/mL (337.97 mM; Need ultrasonic)
储存条件Store at -20°C
General tipsFor obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping ConditionEvaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
产品描述

NX-13 is a first-in-class, orally active and gut-restricted agent that selectively targets and activates the NLRX1 pathway to induce immunometabolic changes. NX-13 results in lower inflammation and responses in inflammatory bowel disease. NX-13 can be used for the research of crohn’s disease and ulcerative colitis[1][2].

NX-13 (0, 500, or 1000 mg/kg; oral gavage; 7 days) reduces ALP levels[2].NX-13 (1 and 10 mg/kg; oral gavage; 0~24 hours) reaches the distal gastrointestinal tract[2].

[1]. Leber A, et al. Activation of NLRX1 by NX-13 Alleviates Inflammatory Bowel Disease through Immunometabolic Mechanisms in CD4+ T Cells. J Immunol. 2019;203(12):3407-3415.
[2]. Leber A, et.al. Exploratory studies with NX-13: oral toxicity and pharmacokinetics in rodents of an orally active, gut-restricted first-in-class therapeutic for IBD that targets NLRX1 [published online ahead of print, 2019 Oct 25]. Drug Chem Toxicol. 2019;1-6.